Company Overview and News

3
AZN / AstraZeneca Plc FORM 8-A12B

2018-08-17 sec.gov
UNITED STATES
AZN

3
AZN / AstraZeneca Plc FORM 6-K (Current Report of Foreign Issuer)

2018-08-17 sec.gov
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AZN

15
Top Research Reports for Cisco, AstraZeneca & Enbridge

2018-08-17 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LMT HD FOX DB SAPGF AZN ENB MPC SE ENB SAP AZN CSCO MS OXY FOXA

4
Merck, Eisai Get FDA Approval for Lenvima Label Expansion

2018-08-17 zacks
Merck and Co., Inc. (MRK - Free Report) along with its Japanese partner Eisai Co., Ltd. announced that their tyrosine kinase inhibitor, Lenvima (lenvatinib) has received FDA approval for an expanded indication. Lenvima, has been approved by the FDA for first-line treatment of unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer which is difficult to treat.
MRK AZN AZN RDN NVS FAF

11
Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

2018-08-17 seekingalpha - 1
Ironwood Pharmaceuticals is a commercial biotechnology company focused on the treatment of gastrointestinal diseases, abdominal pain, and gout.
IRWD SGYP BIIB AGN AZN SGYPW SCMP SNY

3
AZN / AstraZeneca Plc FORM 424B2 (Prospectus)

2018-08-16 sec.gov
CALCULATION OF REGISTRATION FEE
AZN

3
AZN / AstraZeneca Plc FORM FWP

2018-08-15 sec.gov
Free Writing Prospectus filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated August 14, 2018 to the Prospectus dated
AZN

3
AZN / AstraZeneca Plc S-8

2018-08-14 sec.gov
As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. 333- &n
AZN

11
Checkpoint Therapeutics: Potential For A Near-Term Run Up

2018-08-14 seekingalpha - 1
Shares have fallen by around 60% since the company´s common stock made its way onto the Nasdaq.
AZN TGTX AZN NHLD CKPT FBIO CLVS

3
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

2018-08-14 zacks
Merck & Co., Inc. (MRK - Free Report) stock has risen 4.2% since the company announced second-quarter earnings on Jul 27.
MRK AZN AMGN AZN INCY

7
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

2018-08-14 zacks - 1
On Aug 13, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”).
4503 IRWD SGYP ALPMY AZN AGN ALPMF AZN SGYPW

3
AZN / AstraZeneca Plc FORM FWP

2018-08-14 sec.gov
Free Writing Prospectus filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated August 14, 2018 to the Prospectus dated November 22, 2016 Registration Statement No. 333-214756
AZN

3
AZN / AstraZeneca Plc FORM 424B2 (Prospectus)

2018-08-14 sec.gov
The information in this preliminary prospectus supplement and accompanying prospectus is not complete and may be changed without notice. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell the securities, and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
AZN

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 046353108